User login
Key clinical point: Among patients with core binding factor (CBF)-acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (allo-HCT) in complete remission (CR), pretransplant measurable residual disease (MRD) predicts posttransplant outcomes differently in patients with t(8;21) and those with inv(16).
Major finding: Pretransplant MRD negativity was associated with lower relapse (hazard ratio [HR], 0.46; P less than .001), overall mortality (HR, 0.72; P = .037), and treatment failure (HR, 0.66; P = .004) among patients with t(8;21) AML but not those with inv(16) AML (all P > .05).
Study details: Findings are from a retrospective analysis of 959 patients with CBF-AML with either t(8;21) AML (n=631) or inv(16) AML (n=328) who underwent first allo-HCT in CR between 2000 and 2018.
Disclosures: This work was supported partly by the Practical Research Project for Allergic Diseases and Immunology from the Japan Agency for Medical Research and Development. The authors declared no conflict of interests.
Source: Konuma T et al. Bone Marrow Transplant. 2021 Jul 16. doi: 10.1038/s41409-021-01409-4.
Key clinical point: Among patients with core binding factor (CBF)-acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (allo-HCT) in complete remission (CR), pretransplant measurable residual disease (MRD) predicts posttransplant outcomes differently in patients with t(8;21) and those with inv(16).
Major finding: Pretransplant MRD negativity was associated with lower relapse (hazard ratio [HR], 0.46; P less than .001), overall mortality (HR, 0.72; P = .037), and treatment failure (HR, 0.66; P = .004) among patients with t(8;21) AML but not those with inv(16) AML (all P > .05).
Study details: Findings are from a retrospective analysis of 959 patients with CBF-AML with either t(8;21) AML (n=631) or inv(16) AML (n=328) who underwent first allo-HCT in CR between 2000 and 2018.
Disclosures: This work was supported partly by the Practical Research Project for Allergic Diseases and Immunology from the Japan Agency for Medical Research and Development. The authors declared no conflict of interests.
Source: Konuma T et al. Bone Marrow Transplant. 2021 Jul 16. doi: 10.1038/s41409-021-01409-4.
Key clinical point: Among patients with core binding factor (CBF)-acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (allo-HCT) in complete remission (CR), pretransplant measurable residual disease (MRD) predicts posttransplant outcomes differently in patients with t(8;21) and those with inv(16).
Major finding: Pretransplant MRD negativity was associated with lower relapse (hazard ratio [HR], 0.46; P less than .001), overall mortality (HR, 0.72; P = .037), and treatment failure (HR, 0.66; P = .004) among patients with t(8;21) AML but not those with inv(16) AML (all P > .05).
Study details: Findings are from a retrospective analysis of 959 patients with CBF-AML with either t(8;21) AML (n=631) or inv(16) AML (n=328) who underwent first allo-HCT in CR between 2000 and 2018.
Disclosures: This work was supported partly by the Practical Research Project for Allergic Diseases and Immunology from the Japan Agency for Medical Research and Development. The authors declared no conflict of interests.
Source: Konuma T et al. Bone Marrow Transplant. 2021 Jul 16. doi: 10.1038/s41409-021-01409-4.